Legaz I, Muro M. Analysis of hepatitis C virus-positive organs in liver transplantation.. World J Hepatol 2022; 14(9): 1840-1843 [PMID: 36185718 DOI: 10.4254/wjh.v14.i9.1840]
Corresponding Author of This Article
Isabel Legaz, PhD, Senior Lecturer, Department of Legal and Forensic Medicine, Biomedical Research Institute, Regional Campus of International Excellence "Campus Mare Nostrum", Faculty of Medicine, University of Murcia, Espinardo, Murcia 30100, Spain. isalegaz@um.es
Research Domain of This Article
Transplantation
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Sep 27, 2022; 14(9): 1840-1843 Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1840
Analysis of hepatitis C virus-positive organs in liver transplantation.
Isabel Legaz, Manuel Muro
Isabel Legaz, Department of Legal and Forensic Medicine, Biomedical Research Institute, Regional Campus of International Excellence "Campus Mare Nostrum", Faculty of Medicine, University of Murcia, Murcia 30100, Spain
Manuel Muro, Department of Immunology Service, Instituto Murciano de Investigación Biosanitaria, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia 30120, Spain
Author contributions: Muro M and Legaz I designed the research, performed the research, and wrote and revised the letter.
Conflict-of-interest statement: There is no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Isabel Legaz, PhD, Senior Lecturer, Department of Legal and Forensic Medicine, Biomedical Research Institute, Regional Campus of International Excellence "Campus Mare Nostrum", Faculty of Medicine, University of Murcia, Espinardo, Murcia 30100, Spain. isalegaz@um.es
Received: May 30, 2022 Peer-review started: May 30, 2022 First decision: July 6, 2022 Revised: July 7, 2022 Accepted: August 30, 2022 Article in press: August 30, 2022 Published online: September 27, 2022
Core Tip
Core Tip: The scarcity of viable organs, which is quite limited, the waiting lists that reflect chronicity and the increase in time to transplantation, and the rate of physical deterioration resulting in death while waiting for a helpful organ for transplantation, promote the search for new ways, strategies, and protocols to increase the group of donors acceptable for transplantation, such as donors in asystole, donors with tumor processes, or donors with previous infection. The application of antivirals against the hepatitis C virus (HCV), with unprecedented success in the elimination of the pathogen, has led to the use of HCV-positive donors as optimal donors for HCV-negative recipients, with survival similar to that of both HCV-negative donors and recipients, which supports the use of these HCV-positive donors without restrictions.
